Next Article in Journal
Effect of an Enhanced Self-Care Protocol on Lymphedema Status among People Affected by Moderate to Severe Lower-Limb Lymphedema in Bangladesh, a Cluster Randomized Controlled Trial
Next Article in Special Issue
Apheresis in Autoimmune Encephalitis and Autoimmune Dementia
Previous Article in Journal
Racial Disparities-Associated COVID-19 Mortality among Minority Populations in the US
Previous Article in Special Issue
Immunoadsorption and Plasma Exchange in Seropositive and Seronegative Immune-Mediated Neuropathies
Open AccessArticle

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption

1
Department of Nephrology and Medical Intensive Care, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, 12203 Berlin, Germany
2
Institute of Medical Immunology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany
3
Berlin-Brandenburg Center for Regenerative Therapies (BCRT), 13353 Berlin, Germany
*
Author to whom correspondence should be addressed.
Shared senior.
J. Clin. Med. 2020, 9(8), 2443; https://doi.org/10.3390/jcm9082443
Received: 13 July 2020 / Accepted: 28 July 2020 / Published: 30 July 2020
(This article belongs to the Special Issue Apheresis in Neurological Disorders)
(1) Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex neuroimmunological disease. There is evidence for an autoimmune mechanism for ME/CFS with an infection-triggered onset and dysfunction of ß2-adrenoreceptor antibodies (ß2AR-AB). In a first proof-of-concept study, we could show that IA was effective to reduce ß2AR-AB and led to improvement of various symptoms. (2) Five of the ME/CFS patients who had clinical improvement following treatment with a five-day IA were retreated in the current study about two years later with a modified IA protocol. The severity of symptoms was assessed by disease specific scores during a follow-up period of 12 months. The antibodies were determined by ELISA. (3) The modified IA treatment protocol resulted in a remarkable similar clinical response. The treatment was well tolerated and 80–90% decline of total IgG and ß2AR-AB was achieved. Four patients showed a rapid improvement in several clinical symptoms during IA therapy, lasting for six to 12 months. One patient had no improvement. (4) We could provide further evidence that IA has clinical efficacy in patients with ME/CFS. Data from our pilot trial warrant further controlled studies in ME/CFS. View Full-Text
Keywords: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; immunoadsorption; ß2 adrenoreceptor autoantibody Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; immunoadsorption; ß2 adrenoreceptor autoantibody
Show Figures

Figure 1

MDPI and ACS Style

Tölle, M.; Freitag, H.; Antelmann, M.; Hartwig, J.; Schuchardt, M.; van der Giet, M.; Eckardt, K.-U.; Grabowski, P.; Scheibenbogen, C. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption. J. Clin. Med. 2020, 9, 2443. https://doi.org/10.3390/jcm9082443

AMA Style

Tölle M, Freitag H, Antelmann M, Hartwig J, Schuchardt M, van der Giet M, Eckardt K-U, Grabowski P, Scheibenbogen C. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption. Journal of Clinical Medicine. 2020; 9(8):2443. https://doi.org/10.3390/jcm9082443

Chicago/Turabian Style

Tölle, Markus; Freitag, Helma; Antelmann, Michaela; Hartwig, Jelka; Schuchardt, Mirjam; van der Giet, Markus; Eckardt, Kai-Uwe; Grabowski, Patricia; Scheibenbogen, Carmen. 2020. "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption" J. Clin. Med. 9, no. 8: 2443. https://doi.org/10.3390/jcm9082443

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop